"Although the effectiveness of ADHD medications has been demonstrated ... concerns remain regarding their potential cardiovascular safety," one research explained. 

This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

The system, designed for patients with uncontrolled hypertension who are unresponsive to medication, uses ultrasound ablation to target nerves in the renal arteries, increasing blood flow. This approval comes just months after an FDA advisory panel voted in favor of the system. 

The study's authors communicated with ChatGPT-4 in both English and Japanese, noting that it appeared to struggle more with the complexities of the Japanese language. 

More than 5,000 women were interviewed about their eating habits from 1985 to 1991, and then researchers followed up with them 30 years later. The full study was published in Alzheimer’s and Dementia.

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects. 

The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved.